frontiers in Pharmacology

CORRECTION
published: 14 August 2020
doi: 10.3389/fphar.2020.01178

Corrigendum: Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase Protein Kinase

Xiaoming Fan[1], Junyan Tao[2], Xin Cai[1], Mangaladoss Fredimoses[3], Junzi Wu[4], Zhihui Jiang[1], Kunpeng Zhang[1] and Shude Li[5,6]**

[1] Henan Joint International Research Laboratory of Veterinary Biologics Research and Application, Anyang Institute of Technology, Anyang, China, [2] Institute of Environmental Safety and Human Health, Wenzhou Medical University, Wenzhou, China, [3] Laboratory of Natural Product Extraction, China-US (Henan) Hormel Cancer Institute, Zhengzhou, China, [4] College of Basic Medical, Yunnan University of Chinese Medicine, Kunming, China, [5] Department of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, China, [6] Yunnan Province Key Laboratory for Nutrition and Food Safety in Universities, Kunming, Yunnan, China

OPEN ACCESS

Edited by:
Jiang-Jiang Qin,
Zhejiang Chinese Medical University, China

Reviewed by:
Qiang Wang,
Nanjing Drum Tower Hospital, China

***Correspondence:**
Kunpeng Zhang
kunpengzhang12@sina.com
Shude Li
shudeli006@163.com

Specialty section:
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

Received: 22 February 2020
Accepted: 20 July 2020
Published: 14 August 2020

Citation:
Fan X, Tao J, Cai X, Fredimoses M, Wu J, Jiang Z, Zhang K and Li S (2020) Corrigendum: Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase Protein Kinase. Front. Pharmacol. 11:1178. doi: 10.3389/fphar.2020.01178

Keywords: eupafolin, esophagus cancer, TOPK, inhibitor, Ay Tsao

A Corrigendum on

Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase Protein Kinase

By Fan X, Tao J, Cai X, Fredimoses M, Wu J, Jiang Z, Zhang K and Li S (2019) Front. Pharmacol. 10:1248. doi: 10.3389/fphar.2019.01248

Xin Cai was not included as an author, and **Xiaoying Zhang** was incorrectly included as an author in the published article. The corrected Author Contributions Statement appears below.

AUTHOR CONTRIBUTIONS

XF designed research, performed research and wrote the paper; JT analyzed the data; MF extracted Eupafolin from Ay Tsao; JW expressed Histone H3 protein; XC, ZJ performed animal research andanalyzed data; SL, KZ designed research and analyzed data.

Furthermore, there was a mistake in **Figure 1D** as published. The TOPK western picture has an extra strip**.** The corrected **Figure 1** appears below.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



FIGURE 1 | Eupafolin binds with TOPK and suppresses TOPK activity in vitro. **(A)** The docking model of eupafolin and TOPK. **(B)** Measurement of affinity between TOPK and eupafolin by MST in standard treated capillaries, and the resulting binding curve was shown. From the resulting binding curve, Kd of 21.3 ± 2.1 is calculated. **(C)** Eupafolin binds directly with TOPK. Sepharose 4B was used for binding and pull-down assay as described in section "Materials and methods." Lane 1 is input control (TOPK protein standard); lane 2 is the negative control, indicating there is no binding between TOPK and beads alone; and, lane 3 indicates that TOPK binds with eupafolin-Sepharose 4B beads. **(D)** Eupafolin inhibits TOPK activity in vitro. The inhibitory effect of eupafolin on TOPK was determined by an in vitro kinase assay. An inactive GST-histone H3 protein was used as the substrate with active TOPK and 100 μM ATP in the reaction buffer. Protein were resolved by 10% SDS-PAGE gel and detected by Western blot. Histogram statistics is the expression of the p-histone H3 in the first line. Data are representatives of results from triplicate experiments. *Significant compared with lane 3 alone, $P < 0.05$.